Wellington Management Group LLP Sells 28,360 Shares of CareDx, Inc (NASDAQ:CDNA)

Wellington Management Group LLP lowered its holdings in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 14.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 165,362 shares of the company's stock after selling 28,360 shares during the period. Wellington Management Group LLP owned 0.31% of CareDx worth $3,540,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of CareDx during the 3rd quarter worth approximately $1,671,000. Geode Capital Management LLC boosted its position in CareDx by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company's stock worth $38,343,000 after purchasing an additional 32,141 shares during the period. Swiss National Bank boosted its position in CareDx by 1.9% during the fourth quarter. Swiss National Bank now owns 98,600 shares of the company's stock worth $2,111,000 after purchasing an additional 1,800 shares during the period. Barclays PLC increased its holdings in shares of CareDx by 123.8% in the third quarter. Barclays PLC now owns 98,505 shares of the company's stock valued at $3,075,000 after purchasing an additional 54,482 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of CareDx by 59.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 327,343 shares of the company's stock valued at $7,008,000 after purchasing an additional 122,356 shares during the period.

CareDx Price Performance

CareDx stock traded down $0.53 during mid-day trading on Thursday, reaching $17.70. 93,719 shares of the company were exchanged, compared to its average volume of 854,346. The company has a fifty day simple moving average of $19.98 and a 200-day simple moving average of $22.56. The firm has a market cap of $980.76 million, a PE ratio of -6.56 and a beta of 2.18. CareDx, Inc has a 12 month low of $7.42 and a 12 month high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $1.46. The business had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. Sell-side analysts anticipate that CareDx, Inc will post -0.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on CDNA shares. Stephens reaffirmed an "overweight" rating and set a $40.00 target price on shares of CareDx in a report on Thursday, February 27th. StockNews.com raised CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. HC Wainwright dropped their price target on CareDx from $26.00 to $25.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Finally, Wells Fargo & Company raised CareDx from an "underweight" rating to an "equal weight" rating and decreased their price objective for the company from $28.00 to $24.00 in a report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $31.83.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.